Novartis AG (NVS): Price and Financial Metrics


Novartis AG (NVS): $83.52

-1.40 (-1.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVS POWR Grades


  • Stability is the dimension where NVS ranks best; there it ranks ahead of 98.95% of US stocks.
  • NVS's strongest trending metric is Stability; it's been moving up over the last 52 weeks.
  • NVS ranks lowest in Momentum; there it ranks in the 18th percentile.

NVS Stock Summary

  • NVS has a market capitalization of $189,384,694,263 -- more than approximately 98.84% of US stocks.
  • With a one year PEG ratio of 117.61, Novartis Ag is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 79.83% of US stocks.
  • In terms of volatility of its share price, NVS is more volatile than just 3.23% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Novartis Ag, a group of peers worth examining would be SAP, ABBV, AZN, TXN, and NVO.
  • NVS's SEC filings can be seen here. And to visit Novartis Ag's official web site, go to www.novartis.com.

NVS Valuation Summary

  • In comparison to the median Healthcare stock, NVS's price/sales ratio is 5.26% higher, now standing at 4.
  • NVS's price/sales ratio has moved down 0.7 over the prior 243 months.
  • Over the past 243 months, NVS's EV/EBIT ratio has gone up 1.9.

Below are key valuation metrics over time for NVS.

Stock Date P/S P/B P/E EV/EBIT
NVS 2021-08-31 4 3.8 23.0 20.2
NVS 2021-08-30 4 3.8 22.8 20.1
NVS 2021-08-27 4 3.8 22.9 20.2
NVS 2021-08-26 4 3.8 22.8 20.1
NVS 2021-08-25 4 3.8 22.9 20.1
NVS 2021-08-24 4 3.8 22.9 20.2

NVS Growth Metrics

  • Its 5 year price growth rate is now at 12.6%.
  • Its 3 year net cashflow from operations growth rate is now at 20.75%.
  • The year over year revenue growth rate now stands at -0.09%.
Over the past 49 months, NVS's revenue has gone up $2,330,000,000.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 51,556 13,423 8,984
2021-03-31 49,884 13,252 7,955
2020-12-31 49,898 13,650 8,072
2020-09-30 49,584 13,185 7,103
2020-06-30 49,528 14,591 7,210
2020-03-31 49,930 13,741 12,142

NVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVS has a Quality Grade of B, ranking ahead of 84.28% of graded US stocks.
  • NVS's asset turnover comes in at 0.406 -- ranking 115th of 681 Pharmaceutical Products stocks.
  • GHSI, BMY, and PBH are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.406 0.691 0.194
2021-03-31 0.393 0.691 0.176
2020-12-31 0.392 0.697 0.182
2020-09-30 0.401 0.700 0.174
2020-06-30 0.412 0.699 0.180
2020-03-31 0.422 0.702 0.276

NVS Stock Price Chart Interactive Chart >

Price chart for NVS

NVS Price/Volume Stats

Current price $83.52 52-week high $98.52
Prev. close $84.92 52-week low $77.04
Day low $83.24 Volume 570,363
Day high $83.72 Avg. volume 1,901,693
50-day MA $86.35 Dividend yield 2.45%
200-day MA $88.91 Market Cap 186.81B

Novartis AG (NVS) Company Bio


Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.


NVS Latest News Stream


Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream


Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study

Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.

Yahoo | October 22, 2021

10 High-Yield Dividend Stocks to Buy According to Ken Fisher

In this article, we discuss the 10 high-yield dividend stocks to buy according to Ken Fisher. If you want to skip our detailed analysis of these stocks, go directly to the 5 High-Yield Dividend Stocks to Buy According to Ken Fisher. Ken Fisher is the chief of Fisher Asset Management, a Washington-based hedge fund with […]

Yahoo | October 22, 2021

The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis

The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis

Yahoo | October 22, 2021

Neuroendocrine Tumor Treatment Market Rapid Growth with Key Focus on Global 2021-2028 | Pfizer, Novartis AG, Ispen, Tarveda Therapeutics, Progenics Pharmaceuticals,

The Latest research study released by CMI Global Neuroendocrine Tumor Treatment Market with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers,

OpenPR | October 21, 2021

Orphan Drugs Market Projection By Top Key Players Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG Market Research Forecast 2028

A new market study, titled Orphan Drugs Market Forecast 2021-2028 has been featured on Fortune Business Insights. ***Get Latest Updated Market Research Report with Free Sample Report Market Overview: The global orphan drugs market size is projected to reach USD 340.84 billion

OpenPR | October 21, 2021

Read More 'NVS' Stories Here

NVS Price Returns

1-mo 0.71%
3-mo -8.54%
6-mo -3.80%
1-year 1.33%
3-year 19.13%
5-year 52.62%
YTD -9.40%
2020 2.08%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8895 seconds.